Linagliptin
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet.[7][8] Linagliptin is a dipeptidyl peptidase-4 inhibitor[7] that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.[7] It is generally less preferred than metformin and sulfonylureas as an initial treatment.[7][9] It is taken by mouth.[7] Common side effects include inflammation of the nose and throat.[7] Serious side effects may include angioedema, pancreatitis, joint pain.[9][7] Use in pregnancy and breastfeeding is not recommended.[9] Linagliptin was approved for medical use in the United States,[10] Japan, the European Union, Canada, and Australia in 2011.[7][11] In 2023, it was the 254th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[12][13] From August 2021, linagliptin became available as a generic medicine in the US.[14] Medical usesLinagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[5] Side effectsLinagliptin may cause severe joint pain.[5][15] Mechanism of actionLinagliptin belongs to a class of drugs called DPP-4 inhibitors.[5] NamesLinagliptin is the international nonproprietary name (INN).[16] Brand names: Trajenta,[17] Tradjenta. See alsoReferences
External links Wikimedia Commons has media related to Linagliptin. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
